# Granite Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/granite-bio

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.granitebio.com/
- Total disclosed funding: $100M
- Latest round: Series B (Apr 24, 2025)
- Investors on record: 5

## About

Based in Basel, Switzerland, and founded in 2021, Granite Bio AG operates as a pre-clinical and clinical stage biotech company focused on developing therapies for inflammation, autoimmunity, and fibrosis. In 2023, Granite Bio AG raised USD 70 million in Series B funding led by Forbion and Sanofi Ventures. Ridgeline, Versant Ventures, and Novartis Venture Fund also participated in the round.

Granite Bio AG, based in Basel, Switzerland, focuses on developing novel therapies for chronic inflammatory, autoimmune, and fibrotic diseases. The company’s lead assets, GRT-001 and GRT-002, aim to target the fundamental biology underlying these conditions. GRT-001 is an antibody designed to deplete pro-inflammatory monocytes, while GRT-002 targets novel disease biology identified through proprietary patient profiling.

## Funding rounds

- Series B, Apr 24, 2025, $70M — Versant Ventures, Novartis Venture Fund, Forbion, Sanofi Ventures, Ridgeline
- Series A, Apr 24, 2025, $30M — Versant Ventures, Novartis Venture Fund

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Ridgeline (https://capitalatlas.ai/funds/ridgeline) — Series B